iBio plans to sell stock, warrants in public offering via Roth Capital

Proceeds slated for developing applications of proprietary technology

By Susanna Moon

Chicago, Jan. 9 - iBio, Inc. plans to issue units of one share and three-quarters of a warrant in a public offering, according to a 424B5 filing with the Securities and Exchange Commission.

The warrants will be exercisable beginning one year and one day from issue and will expire on the second anniversary of the date they became exercisable.

Purchasers will receive only common shares and warrants. Units will not be issued. The common stock and the warrants may be transferred separately upon issuance.

The company's stock (NYSE Amex: IBIO) closed at $0.89 per share on Jan. 6.

Proceeds will be used for operating costs, including continuing to develop applications of the company's proprietary technology, business development and for other general corporate purposes.

Roth Capital Partners, LLC is the underwriter.

The biotechnology company is based in Newark, Del.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.